Flibanserin (Addyi™) is chemically described as a benzimidazole and is being developed by Sprout Pharmaceuticals for the treatment of hypoactive sexual desire disorder (HSDD). The drug has a high affinity for serotonin 5-HT1A and 5-HT2A receptors (5-HT1A agonist/5-HT2A antagonist) and is believed to treat HSDD by increasing levels of dopamine and noradrenaline and lowering levels of serotonin in the brain. Flibanserin has been approved in the USA for the treatment of premenopausal women with acquired, generalized HSDD. Earlier phase III development of the agent for HSDD in the EU and Canada had been discontinued by Boehringer Ingelheim, following regulatory feedback. Boehringer Ingelheim had also evaluated flibanserin for the treatment of depression but, due to displaying very mild antidepressant activity, its development in this indication was discontinued. This article summarizes the milestones in the development of flibanserin leading to its first approval for HSDD.
KeywordsPremenopausal Woman Sexual Dysfunction Sexual Desire Female Sexual Function Index Etravirine
The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. E. D. Deeks is a salaried employee of Adis, Springer SBM.
- 3.American Psychiatric Association. Diagnostic and statistical manual pf mental disorders. 4th ed. Washington, DC: American Psychiatric Press; 2000.Google Scholar
- 5.US FDA. FDA approves first treatment for sexual desire disorder. Addyi approved to treat premenopausal women [media release]. 18 Aug 2015. http://www.fda.gov.
- 6.Sprout Pharmaceuticals Inc. Addyi (flibanserin) tablets, for oral use: US prescribing information 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf. Accessed 20 Aug 2015.
- 7.Hayes E. FDA position on female sexual desire disorders. Pharm Approvals Monthly. Posted 18 June 2013. Article ID 06130601002 [online resource].Google Scholar
- 8.Boehringer Ingelheim. Following regulatory feedback Boehringer Ingelheim decides to discontinue flibanserin development [media release]. 8 Oct 2010. http://www.boehringer-ingelheim.com.
- 9.Sprout Pharmaceuticals. Sprout Pharmaceuticals confirms resubmission to FDA of flibanserin for treatment of pre-menopausal hypoactive sexual desire disorder [media release]. 26 Jun 2013. http://www.sproutpharma.com.
- 10.Sprout Pharmaceuticals. Sprout Pharmaceuticals appeals FDA decision on New Drug Application for flibanserin to treat hypoactive sexual desire disorder in premenopausal women [media release]. 11 Dec 2013. http://www.sproutpharma.com.
- 11.Sprout Pharmaceuticals. Sprout Pharmaceuticals resubmits flibanserin New Drug Application for the treatment of hypoactive sexual desire disorder in premenopausal women [media release]. 17 Feb 2015. http://www.sproutpharma.com.
- 12.Sprout Pharmaceuticals. Sprout Pharmaceuticals receives clear guidance from FDA on path forward to resubmit New Drug Application for flibanserin, the first potential medical treatment for hypoactive sexual desire disorder in premenopausal women [media release]. 11 Feb 2014. http://www.sproutpharma.com.
- 13.US FDA. NDA 22526 Addyi™ (flibanserin): Risk Evaluation and Mitigation Strategy (REMS). 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526REMS.pdf. Accessed 7 Sep 2015.
- 21.Ferger B, Shimasaki M, Ceci A, et al. Flibanserin, a drug intended for treatment of hypoactive sexual desire disorder in pre-menopausal women, affects spontaneous motor activity and brain neurochemistry in female rats. Naunyn Schmiedebergs Arch Pharmacol. 2010;381(6):573–9.CrossRefPubMedGoogle Scholar
- 26.Clayton A, Jayne C, Jacobs M, et al. Efficacy of flibanserin as a potential treatment for hypoactive sexual desire disorder in North American premenopausal women: results from the DAHLIA trial [abstract PS-02-008]. J Sex Med. 2009;6(Suppl 5):408–9.Google Scholar
- 30.Nappi R, Dean J, van Lunsen R, et al. Efficacy of flibanserin as a potential treatment for hypoactive sexual desire disorder in European premenopausal women: results from the ORCHID trial [abstract no. PS-02-009]. J Sex Med. 2009;6(Suppl 5):409.Google Scholar
- 35.Sprout Pharmaceuticals Inc. Flibanserin evaluation over 28 additional weeks in hypoactive sexual desire disorder [clinicaltrials.gov identifier NCT00601367]. 2014. https://www.clinicaltrials.gov. Accessed 7 Sep 2015.
- 36.Natarajan K, Sicard E, Kay GG, et al. Efficacy and sedation-related safety of flibanserin in premenopausal women [abstract no. 117]. J Sex Med. 2015;12(Suppl 2):143.Google Scholar
- 37.Croft H, Mulroy A, Sambunaris A, et al. A 12-week, randomized, double-blind, placebo-controlled, phase III safety trial of flibanserin tablets (100 MG Q.D.) in women taking a selective serotonin or serotoninnorepinephrine reuptake inhibitor [abstract no. 18]. J Sex Med. 2012;9(9 Suppl 3):168.Google Scholar